Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit 

Rhea-AI Summary

On March 11, 2021, Annovis Bio, ANVS, announced that Dr. Maria Maccecchini, its Founder and CEO, will attend the Q1 Virtual Investor Summit from March 23-25, 2021. Dr. Maccecchini's presentation is scheduled for March 24 at 11:30 AM ET. The summit aims to connect smallcap and microcap companies with investors, featuring 100 companies and over 300 participants.

For registration details, visit www.investorsummitgroup.com. Annovis focuses on developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's.

BERWYN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual Investor Summit.  

Event	Q1 Investor Summit
Date	March 23-25th, 2021
Presentation	March 24th @ 11:30AM ET
Location	https://zoom.us/webinar/register/WN_LKCiDrrKROa4nLfrPKSiAA

About The Investor Summit
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors. 

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com 

Contact: 
Brittney Blocker at brittney@investorsummitgroup.com

ABOUT Annovis Bio, Inc
Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients. For more information on Annovis, please visit the company's website: www.annovisbio.com.

Wire Service Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
Editor@InvestorWire.com

 

FAQ

What is the date of the Q1 Investor Summit for Annovis Bio (ANVS)?

The Q1 Investor Summit will take place from March 23-25, 2021.

When will Dr. Maria Maccecchini from Annovis Bio (ANVS) present at the Investor Summit?

Dr. Maria Maccecchini's presentation is scheduled for March 24, 2021, at 11:30 AM ET.

How can I register for the Q1 Investor Summit featuring Annovis Bio (ANVS)?

You can request complimentary investor registration at www.investorsummitgroup.com.

What type of company is Annovis Bio (ANVS)?

Annovis Bio is a clinical-stage company focused on developing drugs for neurodegenerative diseases.

What diseases does Annovis Bio (ANVS) aim to treat?

Annovis Bio focuses on Alzheimer's disease, Parkinson's disease, and Alzheimer's in Down Syndrome.